EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics
Today's Latest Price: $0.87 USD
Jun 1 9:40am Add EYPT to Watchlist Sign Up EYPT Stock Summary As for revenue growth, note that EYPT's revenue has grown 356.96% over the past 12 months; that beats the revenue growth of 98.1% of US companies in our set. In terms of volatility of its share price, EYPT is more volatile than 81.09% of stocks we're observing. Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EYPT comes in at -53.87% -- higher than that of just 8.4% of stocks in our set. Stocks with similar financial metrics, market capitalization, and price volatility to EyePoint Pharmaceuticals Inc are PAR, PLT, RWLK, AVGR, and GIGA. Visit EYPT's SEC page to see the company's official filings. To visit the company's web site, go to eyepointpharma.com. EYPT Price/Volume Stats
108.46M EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio
EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.
EYPT Latest News Stream
All News Types Acquisition Earnings Insider Buying Mgmt Change New Coverage (Bullish) Product News PT Set (Bullish) Rating Reiterated (Bullish) Resumes Coverage (Bullish) Stock Offering
Event/Time News Detail Loading, please wait... Latest EYPT News From Around the Web
Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
WATERTOWN, Mass., May 26, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call
WATERTOWN, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and…
- Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled…
Read More 'EYPT' Stories Here
EYPT Price Returns
17.27% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8038 seconds.